Eligible patients had a primary procedure for an interventional or diagnostic CV procedure defined by ICD-9 and/or Current Procedural Terminology (CPT Ò ) codes, inpatient admission, and LOCM or iso-osmolar CM agent. CM agents were identified by Standard Charge Master codes and text mining algorithms. One iso-osmolar CM, iodixanol, was identified. Six LOCMs were identified: iohexol, ioversol, iopamidol, ioxaglate, ioxilan, and iopromide. AKI and CIAKI events were determined by ICD-9 diagnosis codes. Multivariable regression analysis was conducted using Ordinary Least Square (OLS) and hospital fixed-effects specifications to assess the relationship between the CM used and CIAKI events for patients with an AKI event.
CONCLUSIONS In this retrospective study of patients with a record of AKI, the use of iso-osmolar CM was associated with fewer CIAKI events compared to LOCMs for patients undergoing inpatient interventional or diagnostic CV procedures. BACKGROUND Chronic kidney disease (CKD) and diabetes mellitus (DM) are associated with increased risk of adverse events in patients with drug eluting stents (DES). Prior studies were conducted on predominantly male patient populations; thus the effect of CKD and DM on outcomes in women with DES remains unclear.
METHODS The purpose of this study was to characterize the independent and combined impact of CKD and DM on outcomes in women undergoing DES implantation. We pooled patient-level data from 26 randomized controlled trials of DES. The primary outcomes of interest were all-cause mortality and major adverse cardiac event (MACE) defined as the composite of all-cause mortality, myocardial infarction or stent thrombosis, at 3 years after DES placement. The study population was stratified into 4 groups: women with neither DM nor CKD, those with DM and no CKD, those with CKD and no DM, and those with both DM and CKD. Women who received a bare metal stent were excluded from this analysis.
RESULTS Out of 4210 women in the pooled dataset for whom baseline creatinine levels were available, 1794 (43.0%) had neither DM nor CKD, 965 (23.0%) had CKD alone, 972 (23.0%) had DM alone, and 479 (11.0%) had both DM and CKD. A stepwise increase in 3-year crude event rates was observed in the transition from no CKD or DM, DM alone, CKD alone,to both CKD and DM (Figure 1) .Following multivariable adjustment, hazard ratios (HR) for all-cause mortality were: 1.81 (95% CI: 1.20 -2.73) in patients with DM alone, 1.38 (95% CI: 0.93 -2.07) in patients with CKD alone, and 3.49 (95% CI: 2.33 -5.23) in patients with both CKD and DM (trend p value <0.0001). Conversely, the adjusted HRs for MACE were 1.24 (95% CI: 0.94-1.64) in patients with DM alone, 1.01 (95% CI: 0.76 -1.34) in patients with CKD alone, and 2.18 (95% CI: 1.63-2.92) in patients with both CKD and DM (trend p value<0.0001).
CONCLUSIONS The presence of both CKD and DM confers a synergistic adverse effect on the risk for long-term MACE in women undergoing PCI. BACKGROUND Contrast-induced acute kidney injury (CIAKI) is a common complication of coronary catheterization. Although several strategies have been proposed, the real efficacy in reducing CIAKI of most of these is debated. We pooled data from randomized trials comparing different preventive strategies for CIAKI in patients undergoing coronary catheterization to define the relative efficacy.
METHODS Randomized trials comparing 2 different strategies were searched in major scientific databases. Trials including patients undergoing procedures requiring contrast media different B152 from coronary catheterization or comparing different doses of the same drug were not considered. Main CIAKI definition was a 25% or 0.5 mg/ml serum creatinine increase from baseline within the first 5 days. Subanalyses according to dissimilar CIAKI definitions were planned. A hierarchical Bayesian network meta-analysis was performed using a random effects consistency model computed by Markov Chain Monte Carlo methods with Gibbs sampling based on 100,000 iterations following discard of 50,000 "burn-in" iterations. Posterior inference was expressed as odds ratio (OR) and 95% credibility interval (CrI).
RESULTS A total of 138 trials (31,720 patients) and 35 different strategies were identified. Most of these treatments, however, were deriving from few small trials. Considering the pooled incidence of CIAKI in the Saline/Placebo group, we estimated that 600 patients were required to reduce by 50% this rate. Imposing this study size filter a total of 93 trials (27,781 patients) and 6 different strategies (Saline/Placebo, Statin, N-Acetylcysteine [NAC], HCO3 [Bicarbonate], NAC+HCO3, Ascorbic Acid) were identified. Statin was the most effective strategy, leading to a significant 60% risk reduction compared with Saline/Placebo, followed by HCO3. Although NAC was the less effective treatment, it was associated with a significant 30% risk reduction compared with Saline/Placebo. The difference between NAC+HCO3 or Ascorbic Acid and Saline/ Placebo was not significant. The network node-split showed inconsistency only for NAC+HCO3 vs Saline/Placebo and there was coherence between direct and indirect evidence for all the others comparisons.
CONCLUSIONS Statin was the most effective preventive strategy for CIAKI, followed by HCO3. Although NAC was the less effective treatment, it seemed to produce a mild CIAKI risk reduction.
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